Featured Announcements: Products of Many Companies Included in the New Version of the New Coronary Pneumonia Diagnosis and Treatment Program_ Securities Times Network

Securities Times e-company news, Yiling Pharmaceutical: Lianhua Qingwen Capsules (granules) are included in the “New Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Ninth Edition)”; Kangyuan Pharmaceutical: Reduning Injection, etc. are included in the new Diagnosis and Treatment Plan for Coronavirus Pneumonia (Trial Version 9); Taiji Group: Angong Niuhuang Pills, etc. are included in the Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Version 9); Yisheng Pharmaceutical: The company’s products are listed in the “Diagnosis and Treatment of Novel Coronavirus Pneumonia” Plan (Trial Version 9)”; Kain Technology: The new coronavirus research projects KW-041 and KW-043 are both in the preclinical research stage; Zenda Essence: the company’s chairman and board secretary are assisting the relevant authorities to investigate; Chip International: Acting Chairman Gao Yonggang was appointed as Chairman; Shenhuo Co., Ltd. performance report: Net profit in 2021 was 3.281 billion yuan, an increase of 815.61% year-on-year; China Mining Resources: Net profit from January to February increased by about 1170.12% year-on-year; Qilianshan: controlling shareholder It is planned to increase the company’s shares by 120 million yuan to 150 million yuan; Tianhai Defense: The subsidiary plans to sign a bulk carrier construction contract of about 747 million yuan; On-machine CNC: Sign a long-term sales contract for monocrystalline silicon wafers of about 4.3 billion yuan; Xinwang Da: It is planned to build a 20GWh power battery and energy storage battery production base with 8 billion yuan.